… sclerosis (MS) should be vaccinated against COVID-19. However, the effect of disease-…
immune response is unknown. We aimed to characterize humoral immunity in mRNA-COVID-19 …

… The therapeutic options that target inflammation and the immune system discussed in this
… been investigated and used for the treatment of COVID-19. While some of these strategies …

… this cytokine, may represent a possible treatment in severe patients [19, 20]. … treatment of
rheumatoid arthritis, could play a key role in the treatment of seriously ill patients with COVID-19 …

… ' immune response when considering therapeutic options such as convalescent plasma
and vaccine candidates for new emerging viruses. Convalescent plasma has demonstrated …

… Baricitinib is another JAK inhibitor that has been identified as a potential therapeutic option
for COVID-19. As with ruxolitinib, preliminary studies have shown some benefit to baricitinib …

… ) in COVID-19 is driven by a unique pattern of immune dysfunction. We studied immune
responses of 54 COVID-19 … ; off-label Tocilizumab treatment of patients was accompanied by …

… Baricitinib is recommended as the therapeutic option for patients with severe COVID-19[70].
In a systematic review and meta-analysis, Song et al[76] showed that compared to the …

… Disparities in the apparent efficacy of appropriate treatments of COVID-19 in … COVID-19
model and evaluate its potential to faithfully model the innate and adaptive human immune …

… and regulating tumor microenvironment including the immune system are the key themes
of … to treatment-related immune dysfunction. The selection of chemotherapeutic treatments, …

… Schematic represents virus-induced host immune system response and viral processing …
have published a detailed review of pharmacologic treatment options for Covid-19 in JAMA (1). …